Stay updated on ASP2215 vs Salvage Chemo in AML with FLT3 Mutation Clinical Trial
Sign up to get notified when there's something new on the ASP2215 vs Salvage Chemo in AML with FLT3 Mutation Clinical Trial page.

Latest updates to the ASP2215 vs Salvage Chemo in AML with FLT3 Mutation Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe date has been updated from January 14, 2025, to February 28, 2025.SummaryDifference0.6%
- Check26 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check33 days agoNo Change Detected
- Check40 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference5%
- Check47 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
- Check62 days agoChange DetectedThe study on ASP2215 versus salvage chemotherapy for AML with FLT3 mutation has been updated with results posted on January 14, 2025, following the previous submission on August 29, 2024.SummaryDifference3%
- Check69 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant revision.SummaryDifference1.0%
Stay in the know with updates to ASP2215 vs Salvage Chemo in AML with FLT3 Mutation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ASP2215 vs Salvage Chemo in AML with FLT3 Mutation Clinical Trial page.